SecBot SecBot
Biotech Drug Report Generated Nov 11, 2026

TUDRIQEV

REPL·Replimune Group, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved (Accelerated Approval)
Time to market
Already approved and commercially available in the U.S. since October 2026.
Why 4/10
TUDRIQEV is already approved and commercially launched with no pending PDUFA or pivotal readout for this drug in the next ~12 months. The defining binary binary (approval) has already passed. The next catalysts are commercial execution and the confirmatory Phase 3 trial, neither of which is a hard dated binary event in the near term.
Actionable Insight NEUTRAL

TUDRIQEV is now a commercial-stage asset, so the focus shifts from regulatory binary to revenue execution. Watch the next quarterly earnings (likely late January 2027) for early sales figures, formulary adoption metrics, and the permanent J-code expected by April 2027. The confirmatory Phase 3 trial data timeline is the next major binary but has no announced readout date yet.

Price Chart

Loading chart...

Executive Summary

TUDRIQEV (vusolimogene oderparepvec, formerly RP1) is Replimune's first commercial product and only the second oncolytic virus therapy ever approved in the U.S. It won FDA accelerated approval on August 6, 2026 for advanced cutaneous melanoma in combination with nivolumab, after a turbulent regulatory journey that included two Complete Response Letters and a 10-3 AdComm vote. The drug launched commercially on October 1, 2026, with early traction of over 15 prescribing institutions. Replimune remains unprofitable (net loss of $57M in Q2 FY2027) and faces the risk that the required confirmatory Phase 3 trial may not validate the accelerated approval. The stock has rebounded from a low of ~$1.70 after the April 2026 CRL to ~$23.28, roughly in line with the analyst consensus price target.

How It Works

TUDRIQEV is a genetically modified herpes simplex virus designed to infect and kill cancer cells directly (oncolysis). It is injected directly into tumors, where it replicates inside cancer cells, causing them to burst. This process also stimulates the immune system to recognize and attack cancer cells throughout the body. It is used in combination with nivolumab (Opdivo), a PD-1 checkpoint inhibitor.

Trial Status

Approved by the FDA on August 6, 2026 under accelerated approval based on the Phase 1/2 IGNYTE trial (NCT03767348). In the registrational cohort of 140 patients with advanced melanoma who progressed on anti-PD-1 therapy, TUDRIQEV plus nivolumab showed a confirmed objective response rate (ORR) of 32.9% with a median duration of response of 33.7 months (per AJMC). A confirmatory Phase 3 trial is required and ongoing as a condition of the accelerated approval. The drug was commercially launched on October 1, 2026, with first patient dosed on October 6, 2026.

The Two-Sided Case

▲ Bull Case5
TUDRIQEV is only the second oncolytic virus therapy ever approved in the U.S. (after Amgen's Imlygic), giving Replimune a first-mover advantage in a novel modality for a large melanoma market.
Early launch metrics are strong: more than 15 institutions prescribed TUDRIQEV in the first three weeks, and the stock jumped 17% on that news on October 29, 2026.
Analyst consensus is bullish: 13 of 15 analysts rate it Buy/Strong Buy, with a mean price target of $23.33 (roughly in line with the current ~$23.28 price) and a high target of $31.
NCCN guidelines list TUDRIQEV as a Category 2A recommendation, and multiple payer policies have been published covering it, supporting rapid formulary access.
The company raised $150 million in August 2026 to fund the commercial launch and confirmatory trial, extending its cash runway.
▼ Bear Case6
The drug was rejected twice by the FDA before finally securing accelerated approval, highlighting significant regulatory skepticism about the clinical data from the single-arm IGNYTE trial.
Accelerated approval requires a confirmatory Phase 3 trial; if that trial fails or shows underwhelming results, the FDA could withdraw the indication.
The company is still deeply unprofitable: a net loss of $57.1 million in Q2 FY2027 and $126.9 million in the first half of fiscal 2027, with no guarantee of when TUDRIQEV will reach profitability.
A securities class action lawsuit has been filed against Replimune alleging misleading statements about the RP1 regulatory strategy, creating legal overhang.
Insider selling: Director Slattery sold $113K in stock on November 9, 2026, and Director Dhingra sold $408K on November 2, 2026, following option exercises.
Short volume on November 10, 2026 was elevated at 64% of off-exchange volume, indicating significant bearish positioning.

Upcoming Catalysts

  • Commercial sales trajectory updates (next quarterly earnings around late January 2027)
  • Permanent J-code expected by April 2027 (facilitates reimbursement)
  • Confirmatory Phase 3 trial data readout (timing not yet specified)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Replimune Group, Inc. CLUSTER REPL ·Originating report

Sources · 12

Hover a chip for the title
1 sec.gov2 bioworld.com3 markets.businessinsider.com4 markets.businessinsider.com5 ajmc.com6 fiercebiotech.com7 fiercepharma.com8 pulse2.com9 nature.com10 healio.com11 seekingalpha.com12 msn.com